Abstract: A tracking liquidity order and related market center and process are disclosed which allow posting market centers (e.g. exchanges) to fill routable, smaller orders that would have otherwise routed off the posting market center. Such tracking liquidity orders increase the liquidity of that posting market center and allow it to execute more orders internally, without having to route them to an away market center.

Abstract: An unpriced order auction and related market center and process are disclosed which allow posting market centers (e.g., exchanges) to schedule an auction that includes unpriced (Market) orders only. Such unpriced order auction executes at the midpoint of the NBBO, ensuring that the cross reflects the best prices in the entire marketplace, while discouraging the manipulation of the auction price on the posting market center. The disclosed auction also executes concurrently, but separately from the regular continuous matching process.

Abstract: A tracking liquidity order and related market center and process are disclosed which allow posting market centers (e.g. exchanges) to fill routable, smaller orders that would have otherwise routed off the posting market center. Such tracking liquidity orders increase the liquidity of that posting market center and allow it to execute more orders internally, without having to route them to an away market center.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: The present invention features methods of administering a therapeutic agent to a patient's lymph nodes by instillation of microparticles or nanoparticles comprising a biocompatible polymer and the therapeutic agent into the patient's bladder. The invention also features methods of modulating a patient's immune response and methods of systemic delivery of a therapeutic agent systemically using the administration methods of the invention.

Abstract: The present invention relates to compositions and methods for delivery of nucleic acids. In particular, the invention provides a polymeric delivery formulation including a nucleic acid to be transfected into a host cell, formulated in a biodegradable polymer having phosphorous-based linkages.

Abstract: Featured are highly useful pharmaceutical compositions that include a microparticle having a polymeric support material preferably adapted to disperse therapeutic agent. In a particular invention embodiment, the support material comprises at least 50% w/w of a homopolymer as described herein. Also featured are methods of making the compositions as well as using same to treat diseases such as bladder cancer.

Abstract: The present invention features methods of administering a therapeutic agent to a patient's lymph nodes by instillation of microparticles or nanoparticles comprising a biocompatible polymer and the therapeutic agent into the patient's bladder. The invention also features methods of modulating a patient's immune response and methods of systemic delivery of a therapeutic agent systemically using the administration methods of the invention.